Published in Cancer Res on September 09, 2014
Inhibition of Tumor Growth and Immunomodulatory Effects of Flavonoids and Scutebarbatines of Scutellaria barbata D. Don in Lewis-Bearing C57BL/6 Mice. Evid Based Complement Alternat Med (2015) 0.82
The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets. Immunol Rev (2017) 0.80
Exploiting IL-17-producing CD4(+) and CD8(+) T cells to improve cancer immunotherapy in the clinic. Cancer Immunol Immunother (2016) 0.79
1α,25-dihydroxyvitamin D3 acts via transforming growth factor-β to up-regulate expression of immunosuppressive CD73 on human CD4(+) Foxp3(-) T cells. Immunology (2015) 0.78
Lack of p53 Augments Antitumor Functions in Cytolytic T Cells. Cancer Res (2016) 0.77
Inhibiting Oxidative Phosphorylation In Vivo Restrains Th17 Effector Responses and Ameliorates Murine Colitis. J Immunol (2017) 0.75
CD73 is expressed by inflammatory Th17 cells in experimental autoimmune encephalomyelitis but does not limit differentiation or pathogenesis. PLoS One (2017) 0.75
CD73-mediated adenosine production promotes stem cell-like properties in mouse Tc17 cells. Immunology (2015) 0.75
Synthetic RORγ agonists regulate multiple pathways to enhance antitumor immunity. Oncoimmunology (2016) 0.75
Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med (2007) 10.00
Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol (2007) 8.31
The three Es of cancer immunoediting. Annu Rev Immunol (2004) 8.20
ATP drives lamina propria T(H)17 cell differentiation. Nature (2008) 8.02
Generation of pathogenic T(H)17 cells in the absence of TGF-β signalling. Nature (2010) 7.50
Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood (2008) 6.81
The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo. Nat Immunol (2009) 6.74
Posttranscriptional control of T cell effector function by aerobic glycolysis. Cell (2013) 6.30
Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med (2013) 5.82
IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med (2009) 5.05
Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood (2009) 4.80
IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc Natl Acad Sci U S A (2004) 4.70
Mitochondria are required for antigen-specific T cell activation through reactive oxygen species signaling. Immunity (2013) 4.08
Ecto-5'-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. J Clin Invest (2002) 4.05
Advances in measuring cellular bioenergetics using extracellular flux. Drug Discov Today (2008) 3.49
Metabolic pathways in immune cell activation and quiescence. Immunity (2013) 3.09
IL-1 acts directly on CD4 T cells to enhance their antigen-driven expansion and differentiation. Proc Natl Acad Sci U S A (2009) 3.07
Th17 cells are long lived and retain a stem cell-like molecular signature. Immunity (2011) 2.64
Increased level of extracellular ATP at tumor sites: in vivo imaging with plasma membrane luciferase. PLoS One (2008) 2.51
Glucose availability regulates IFN-gamma production and p70S6 kinase activation in CD8+ effector T cells. J Immunol (2005) 2.51
Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function. J Clin Invest (2013) 2.50
Raising the bar: the curative potential of human cancer immunotherapy. Sci Transl Med (2012) 2.04
Human TH17 cells are long-lived effector memory cells. Sci Transl Med (2011) 1.99
Priming microenvironments dictate cytokine requirements for T helper 17 cell lineage commitment. Immunity (2011) 1.98
Stat3 and Gfi-1 transcription factors control Th17 cell immunosuppressive activity via the regulation of ectonucleotidase expression. Immunity (2012) 1.82
Th9 cells promote antitumor immune responses in vivo. J Clin Invest (2012) 1.80
CD73: a novel target for cancer immunotherapy. Cancer Res (2010) 1.52
Th1 versus Th17: are T cell cytokines relevant in multiple sclerosis? Biochim Biophys Acta (2010) 1.50
T helper 17 cell heterogeneity and pathogenicity in autoimmune disease. Trends Immunol (2011) 1.47
CD73-deficient mice are resistant to carcinogenesis. Cancer Res (2012) 1.38
Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs. Clin Cancer Res (2013) 1.36
Cutting edge: the pathogenicity of IFN-γ-producing Th17 cells is independent of T-bet. J Immunol (2013) 1.32
Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists. Clin Exp Immunol (2009) 1.28
Prospects for TIM3-Targeted Antitumor Immunotherapy. Cancer Res (2011) 1.17
Generation of anti-inflammatory adenosine by leukocytes is regulated by TGF-β. Eur J Immunol (2011) 1.16
IL-12 and type I interferon prolong the division of activated CD8 T cells by maintaining high-affinity IL-2 signaling in vivo. J Exp Med (2013) 1.16
FoxP3+RORgammat+ T helper intermediates display suppressive function against autoimmune diabetes. J Immunol (2010) 1.15
Human Th17 cells express high levels of enzymatically active dipeptidylpeptidase IV (CD26). J Immunol (2012) 1.08
Cutting edge: OFF cycling of TNF production by antigen-specific CD8+ T cells is antigen independent. J Immunol (2000) 1.05
A quantitative increase in regulatory T cells controls development of vitiligo. J Invest Dermatol (2013) 1.05
Expression and clinical significance of CD73 and hypoxia-inducible factor-1α in gastric carcinoma. World J Gastroenterol (2013) 1.03
IL-1 enhances expansion, effector function, tissue localization, and memory response of antigen-specific CD8 T cells. J Exp Med (2013) 1.03
Production of adenosine by ectonucleotidases: a key factor in tumor immunoescape. J Biomed Biotechnol (2012) 1.01
Tumor-specific IL-9-producing CD8+ Tc9 cells are superior effector than type-I cytotoxic Tc1 cells for adoptive immunotherapy of cancers. Proc Natl Acad Sci U S A (2014) 1.00
Interleukin-23 promotes Th17 differentiation by inhibiting T-bet and FoxP3 and is required for elevation of interleukin-22, but not interleukin-21, in autoimmune experimental arthritis. Arthritis Rheum (2010) 0.96
A coreceptor-independent transgenic human TCR mediates anti-tumor and anti-self immunity in mice. J Immunol (2012) 0.94
T cells undergo rapid ON/OFF but not ON/OFF/ON cycling of cytokine production in response to antigen. J Immunol (2005) 0.91
Opportunities and challenges for anti-CD73 cancer therapy. Immunotherapy (2012) 0.87
Is TGF-beta a stemness regulator? Blood (2009) 0.78